01 January 2002
Nefiracetam ameliorates associative learning impairment in the scopolamine-injectedolder rabbit.
John Green, Boris Heifets, Jonathan Pak, Michelle Pak, Diana Woodruff-PakMed Sci Monit 2002; 8(4): BR105-112 :: ID: 420883
Abstract
BACKGROUND: The cognition-enhancing drug, nefiracetam, is in Phase IIIclinical trials to treat memory impairment in Alzheimer's disease (AD). Nefiracetam ameliorates acquisitionof delay eyeblink classical conditioning in older rabbits, a form of associative learning with strikingbehavioral and neurobiological similarities in rabbits and humans. In both species, delay eyeblink conditioningengages the septo-hippocampal cholinergic system and is disrupted when the cholinergic system is antagonized.Delay eyeblink classical conditioning is impaired in normal aging and severely disrupted in AD. MATERIAL/METHODS:To test further the efficacy of nefiracetam in an animal model that mimics some of the neurobiologicaland behavioral effects present in AD, we tested 56 older rabbits assigned to 7 treatment groups in the750 ms delay eyeblink conditioning procedure. Older rabbits were injected with 1.5 mg/kg scopolamineto simulate disruption of the cholinergic system in AD. Three doses of nefiracetam (5, 10, or 15 mg/kg)were also injected in older rabbits receiving 1.5 mg/kg scopolamine. Control groups were treated with1.5 mg/kg scopolamine + vehicle, vehicle alone, or explicitly unpaired presentations of conditioningstimuli and vehicle or 1.5 mg/kg scopolamine + 15 mg/kg nefiracetam. RESULTS: Rabbits injected with 1.5mg/kg scopolamine alone were impaired, but a dose of 15 mg/kg nefiracetam reversed significantly thebehavioral impairment. CONCLUSIONS: Nefiracetam had ameliorating effects on a task impaired in AD inan animal model of AD: older rabbits with cholinergic system antagonism.
Keywords: Aging, Association Learning, Cholinergic Antagonists, Conditioning, Eyelid, Hippocampus, Learning Disorders, Nootropic Agents, Pyrrolidinones, Reaction Time, Research Support, Non-U.S. Gov, Scopolamine, Septum Pellucidum, Specific Pathogen-Free Organisms, Stimulation, Chemical
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952